Roivant Sciences Financials - Benzinga

SPY772.04+0.09%QQQ745.40+0.12%BTC/USD84,765.12+0.39%DIA517.72+0.04%GLD393.05−0.09%TLT79.38+0.08%

Roivant Sciences Ltd

ROIVNASDAQ

Trade with Public

Trade with Public

$35.80

-0.33-0.91%

At close: Sep 25, 5:00 PM EST

$35.80

N/A

After Hours: Sep 25, 4:35 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Roivant Sciences Financials

Roivant Sciences (ROIV) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate

Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 36 percent decrease over losses of $(0.25) per share from

Benzinga Newsdesk

S&P 500 Rebounds Ahead Of Nvidia's Print, Oil Sinks 5% On Iran Truce Hopes: Stock Market Today

U.S. stocks halt a three-day slide as oil tumbles 5% on revived Iran truce hopes, easing inflation fears ahead of Nvidia's results after the close.

Piero Cingari

Earnings Scheduled For May 20, 2026

Benzinga Insights

PRO
Roivant Sciences Q4 Adj. EPS $(0.27) Beats $(0.34) Estimate

Benzinga Newsdesk

PRO
Roivant Sciences Q4 Sales $2.520M Miss $3.820M Estimate

Benzinga Newsdesk

Roivant Stock Soars On Experimental Skin Drug Delivering 100% Response - Why It Matters

Roivant shares surged after its skin disease drug brepocitinib showed strong Phase 2 results, with high response rates, early benefits, and no serious safety issues.

Vandana Singh

© 2026 Benzinga | All Rights Reserved